07:21 AM EST, 02/03/2026 (MT Newswires) -- Seegnal (SEGN.V) after markets closed on Monday announced its "deepened partnership" with Tel Aviv Sourasky Medical Center.

The company said that Sourasky Medical Center, which it said is Israel's second-largest public hospital, has expanded its use of Seegnal's Prescription Intelligence Platform to further enhance clinical decision-making.

In a statement, the company noted that, pursuant to the expanded deployment, Seegnal's patented platform is used across multiple departments at Sourasky Medical Center, supporting physicians and care teams with real-time, patient-specific medication decision support at the point of care.

"The expanded deployment enables a consistent patient-centric medication safety standard across inpatient and outpatient settings, while maintaining clinical efficiency and minimizing alert fatigue," said the company.

The company said that the expanded deployment period effectively began on Jan. 1, 2026 and runs through Dec. 31, 2027, with an option to extend the engagement through Dec. 31, 2031.

Under the agreement, Seegnal's prescription intelligence platform will support approximately 1,200 clinicians and 2,050 medical team members, who will use the system on a daily basis as part of routine clinical workflows, said the company.

"Sourasky Medical Center represents one of the most advanced clinical environments within public health systems worldwide," said Elad Bibi-Aviv, chief executive officer of Seegnal. "The expansion of our deployment reflects strong confidence in the clinical, operational, and economic value Seegnal delivers at scale."

Bibi-Aviv added, "Sourasky Medical Center's role as a global reference site further validates our platform's maturity and scalability. This deployment demonstrates that patient-specific prescribing intelligence can improve safety and efficiency while supporting sustainable economics for large medical centers."